报价延迟最少15分钟:2025/07/20 15:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.75 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.20/--
|
|
企业价值
407.61M
|
| 资产负债 |
|
每股账面净值
7.04
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 15:11 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
